Meta-analysis in people with cystic fibrosis: elexacaftor/tezacaftor/ivacaftor was associated with lower 120-min glucose (MD -24.30 mg/dL) and HbA1c (MD -0.44%), more so with earlier start. Other CFTR modulators showed no significant change.
Meta-analysis
Kiss et al. CFTR Modulator Therapy and Glycemic Control: A Meta-Analysis